2 terminated, 1 active not recruiting, 1 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Pilocytic Astrocytoma: new trials by email Literature Review of Pilocytic Astrocytoma trials Research Report on Pilocytic Astrocytoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Dabrafenib, trametinib, Carboplatin - Diffuse Astrocytoma, Anaplastic Astrocytoma | Phase 2 | Completed | Novartis Pharmaceuticals | 151 | 2017-12-28 | 2023-12-13 |
| Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors MRI-guided laser ablation, Doxorubicin, Etoposide - Glioma, Pilocytic Astrocytoma | Phase 2 | Terminated | Washington University School of Medicine | 6 | 2015-08-14 | 2024-11-01 |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Mebendazole, Vincristine, Carboplatin - Pilomyxoid Astrocytoma, Pilocytic Astrocytoma | Phase 1 / Phase 2 | Active not recruiting | Julie Krystal | 10 | 2013-10-22 | 2026-08-06 |
Astrocytoma (4) · Glioblastoma (3) · Glioma (3) · Oligodendroglioma (2) · Optic Nerve Glioma (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Ganglioglioma (1) · Ganglioneuroma (1) · Gliosarcoma (1) · Melanoma (1) · Neurocytoma (1) · Pancreatic Neoplasms (1) · Thyroid Cancer, Papillary (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Neuroepithelial (4) · Neuroectodermal Tumors (4) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Brain Diseases (2) · Brain Neoplasms (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Cranial Nerve Diseases (2)
Carboplatin (2) · Vincristine (2) · Bevacizumab (1) · Doxorubicin (1) · Dynamic Contrast Enhanced Magnetic Resonance Imaging (1) · Etoposide (1) · Irinotecan (1) · Mebendazole (1) · Perfusion Magnetic Resonance Imaging (1) · Temozolomide (1) · dabrafenib (1) · etoposide phosphate (1) · tovorafenib (1) · trametinib (1)
Day One Biopharmaceuticals, Inc. (1) · Julie Krystal (1) · Novartis Pharmaceuticals (1) · Washington University School of Medicine (1)
United States (4) · Australia (2) · Belgium (2) · Canada (2) · France (2) · Spain (2) · Argentina (1) · Brazil (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1)
Andrew Cluster, M.D. (1) · Julie Krystal, MD (1)
PMID 34331515, PMID 37610803, PMID 37643378, PMID 37733309, PMID 41740060, PMID 42826365
2015 (1)